INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $159,000 | -39.8% | 10,681 | -19.2% | 0.00% | -100.0% |
| Q2 2021 | $264,000 | -0.4% | 13,227 | +15.0% | 0.00% | 0.0% |
| Q1 2021 | $265,000 | -1.1% | 11,497 | +6.1% | 0.00% | 0.0% |
| Q4 2020 | $268,000 | -23.9% | 10,834 | +27.6% | 0.00% | -50.0% |
| Q3 2020 | $352,000 | -20.2% | 8,493 | -7.7% | 0.00% | 0.0% |
| Q2 2020 | $441,000 | +8.9% | 9,201 | +43.0% | 0.00% | -33.3% |
| Q1 2020 | $405,000 | -70.5% | 6,434 | -42.0% | 0.00% | -50.0% |
| Q4 2019 | $1,374,000 | +68.2% | 11,091 | -9.9% | 0.01% | +20.0% |
| Q3 2019 | $817,000 | -17.4% | 12,308 | -0.9% | 0.01% | -16.7% |
| Q2 2019 | $989,000 | -33.7% | 12,424 | -6.8% | 0.01% | -33.3% |
| Q1 2019 | $1,491,000 | +13.7% | 13,331 | +2.5% | 0.01% | 0.0% |
| Q4 2018 | $1,311,000 | -33.1% | 13,005 | -16.1% | 0.01% | -30.8% |
| Q3 2018 | $1,959,000 | +47.6% | 15,507 | -2.0% | 0.01% | +44.4% |
| Q2 2018 | $1,327,000 | +78.4% | 15,816 | +30.8% | 0.01% | +80.0% |
| Q1 2018 | $744,000 | -9.0% | 12,092 | -13.7% | 0.01% | -16.7% |
| Q4 2017 | $818,000 | -3.2% | 14,004 | -3.8% | 0.01% | -25.0% |
| Q3 2017 | $845,000 | -47.2% | 14,562 | +10.2% | 0.01% | -50.0% |
| Q2 2017 | $1,599,000 | +3.8% | 13,209 | -3.0% | 0.02% | 0.0% |
| Q1 2017 | $1,540,000 | -14.8% | 13,616 | -18.2% | 0.02% | -20.0% |
| Q4 2016 | $1,808,000 | -32.1% | 16,642 | +2.9% | 0.02% | -45.9% |
| Q3 2016 | $2,661,000 | -1.3% | 16,169 | -14.4% | 0.04% | +5.7% |
| Q2 2016 | $2,695,000 | +13.8% | 18,890 | +2.4% | 0.04% | +6.1% |
| Q1 2016 | $2,369,000 | -21.5% | 18,439 | -8.8% | 0.03% | -10.8% |
| Q4 2015 | $3,019,000 | -4.6% | 20,213 | +5.9% | 0.04% | -15.9% |
| Q3 2015 | $3,165,000 | -34.4% | 19,083 | -4.5% | 0.04% | -34.3% |
| Q2 2015 | $4,823,000 | -8.7% | 19,983 | +6.7% | 0.07% | +8.1% |
| Q1 2015 | $5,283,000 | +130.2% | 18,731 | +27.3% | 0.06% | +129.6% |
| Q4 2014 | $2,295,000 | -4.3% | 14,709 | +102.3% | 0.03% | -10.0% |
| Q1 2014 | $2,398,000 | +666.1% | 7,270 | +60.6% | 0.03% | +328.6% |
| Q3 2013 | $313,000 | – | 4,528 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |